Tirzepatide vs Retatrutide: Research Profiles of the Dual and Triple Agonists
Incretin research moved quickly from single-receptor GLP-1 agonists to tirzepatide's dual agonism and then retatrutide's triple agonism. The two compounds are often grouped together, but both their pharmacology and the maturity of the supporting evidence differ. Those distinctions matter when designing research.
Receptor profiles
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors | GIP + GLP-1 (dual) | GIP + GLP-1 + glucagon (triple) |
| Receptor balance | GIP-biased — full GIP agonist, weaker GLP-1 activity than native GLP-1 | Engineered imbalance: strongest at GIP, moderate glucagon, attenuated GLP-1 |
| Structure | 39 AA, C20 fatty-diacid, once-weekly kinetics | 39 AA, C20 fatty-diacid, once-weekly kinetics |
| Development status | Approved (type 2 diabetes, obesity) | Phase 3 (TRIUMPH program) — not approved anywhere |
What the published trials show
Tirzepatide has a completed evidence base, including the SURPASS program in diabetes and SURMOUNT in obesity. SURMOUNT-1 reported mean weight reductions up to ~21% over 72 weeks at the highest dose. That result established dual agonism as superior to GLP-1 alone for weight endpoints.
Retatrutide has phase 2 data published in the New England Journal of Medicine in 2023. At the top dose, mean weight reduction reached ~24% at 48 weeks, and the trajectory had not yet plateaued at study end. This was the strongest mid-stage result reported for any incretin compound. Phase 3 outcomes are pending. Until they publish, its profile rests on a few hundred participants rather than tens of thousands.
The glucagon question
The glucagon receptor is the scientifically interesting part of retatrutide's profile. Glucagon agonism raises energy expenditure and drives hepatic fat oxidation; phase 2 sub-studies reported marked liver-fat reductions. Historically, however, glucagon agonism risked hyperglycemia, which the GIP/GLP-1 components appear to offset. Phase 3 will show whether that balance holds at scale. Comparative receptor-signaling work in vitro remains active while that question is open.
Choosing a research compound
- Benchmarking against an approved, fully characterized comparator → tirzepatide (GLP-2 T, 40mg vials).
- Studying glucagon-receptor contribution, energy expenditure, or triple-agonist pharmacology → retatrutide (GLP-3 Reta, 24mg vials).
- Single-receptor baseline for either → semaglutide (see its research overview).
Both compounds are large, lipidated peptides and require the same handling as semaglutide: gentle reconstitution, refrigeration, and no shaking. For research use only — not for human or veterinary use.